ImClone Hammered as Sales Lag Estimates

ImClone Hammered as Sales Lag Estimates
Scandal-plagued ImClone Systems may have fallen off the road to recovery.
While the company’s second-quarter earnings beat Wall Street estimates, the stock plunged yesterday on disappointing sales of the company’s key cancer drug.


Comments are closed.

Do NOT follow this link or you will be banned from the site!
%d bloggers like this: